201 related articles for article (PubMed ID: 33177152)
21. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
Pender A; Jones RL
Clin Pharmacol; 2017; 9():159-164. PubMed ID: 29270033
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
[TBL] [Abstract][Full Text] [Related]
23. Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA; Cecchini M; Ni Choileain S; Jones R
Drugs Today (Barc); 2017 Apr; 53(4):247-255. PubMed ID: 28492292
[TBL] [Abstract][Full Text] [Related]
24. Olaratumab for the treatment of soft-tissue sarcoma.
Pender A; Jones RL
Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
[TBL] [Abstract][Full Text] [Related]
25. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma.
Vornicova O; Haim N; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Oct; 84(4):919-923. PubMed ID: 31410509
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
[TBL] [Abstract][Full Text] [Related]
31. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Schöffski P; Bahleda R; Wagner AJ; Burgess MA; Junker N; Chisamore M; Peterson P; Szpurka AM; Ceccarelli M; Tap WD
Clin Cancer Res; 2023 Sep; 29(17):3320-3328. PubMed ID: 37382656
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Gerber DE; Swanson P; Lopez-Chavez A; Wong L; Dowlati A; Pennell NA; Cronier DM; Qin A; Ilaria R; Cosaert J; Shahir A; Baggstrom MQ
Lung Cancer; 2017 Sep; 111():108-115. PubMed ID: 28838379
[TBL] [Abstract][Full Text] [Related]
33. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Hakenberg OW; Perez-Gracia JL; Castellano D; Demkow T; Ali T; Caffo O; Heidenreich A; Schultze-Seemann W; Sautois B; Pavlik I; Qin A; Novosiadly RD; Shahir A; Ilaria R; Nippgen J
Eur J Cancer; 2019 Jan; 107():186-195. PubMed ID: 30573277
[TBL] [Abstract][Full Text] [Related]
34. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
[TBL] [Abstract][Full Text] [Related]
35. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.
Ehnman M; Missiaglia E; Folestad E; Selfe J; Strell C; Thway K; Brodin B; Pietras K; Shipley J; Östman A; Eriksson U
Cancer Res; 2013 Apr; 73(7):2139-49. PubMed ID: 23338608
[TBL] [Abstract][Full Text] [Related]
36. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
Liang M; Wang B; Schneider A; Vainshtein I; Roskos L
AAPS J; 2020 Nov; 23(1):4. PubMed ID: 33210183
[TBL] [Abstract][Full Text] [Related]
37. Olaratumab Approved for Soft-Tissue Sarcoma.
Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
[TBL] [Abstract][Full Text] [Related]
38. Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC.
Kilvaer TK; Rakaee M; Hellevik T; Vik J; Petris L; Donnem T; Strell C; Ostman A; Busund LR; Martinez-Zubiaurre I
Sci Rep; 2019 Jul; 9(1):10163. PubMed ID: 31308421
[TBL] [Abstract][Full Text] [Related]
39. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
40. Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration.
Kikuchi A; Pradhan-Sundd T; Singh S; Nagarajan S; Loizos N; Monga SP
Am J Pathol; 2017 Oct; 187(10):2273-2287. PubMed ID: 28734947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
